Becton, Dickinson and Company Peer Comparison
| Metric | Value | Ranking | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $69.3 Billion | 1/11 | BDX $69.3B |
RMD $35.1B |
WST $21.7B |
COO $21.5B |
HOLX $18.5B |
TFX $11.5B |
RGEN $8.0B |
XRAY $5.1B |
ICUI $4.4B |
HAE $4.1B |
ANGO $310.9M |
| Gross Margin | 46% | 8/11 | COO 61% |
RMD 58% |
HOLX 56% |
TFX 56% |
ANGO 54% |
XRAY 52% |
HAE 50% |
BDX 46% |
RGEN 45% |
ICUI 35% |
WST 33% |
| Profit Margin | 10% | 6/11 | RMD 24% |
HOLX 19% |
WST 16% |
HAE 11% |
TFX 11% |
BDX 10% |
COO 10% |
RGEN 2% |
XRAY 0% |
ICUI -4% |
ANGO -19% |
| EBITDA margin | 26% | 4/11 | HOLX 33% |
RMD 31% |
COO 28% |
BDX 26% |
TFX 26% |
WST 24% |
HAE 22% |
XRAY 16% |
ICUI 13% |
RGEN 13% |
ANGO -5% |
| Quarterly Revenue | $5.0 Billion | 1/11 | BDX $5.0B |
RMD $1.2B |
HOLX $1.0B |
COO $1.0B |
XRAY $984.0M |
TFX $749.7M |
WST $702.0M |
ICUI $595.8M |
HAE $336.2M |
RGEN $154.1M |
ANGO $71.0M |
| Quarterly Earnings | $487.0 Million | 1/11 | BDX $487.0M |
RMD $292.2M |
HOLX $194.5M |
WST $111.3M |
COO $104.7M |
TFX $80.0M |
HAE $38.4M |
RGEN $3.3M |
XRAY -$4.0M |
ANGO -$13.4M |
ICUI -$21.4M |
| Quarterly Free Cash Flow | $1.1 Million | 1/11 | BDX $1.1B |
RMD $415.2M |
HOLX $361.9M |
XRAY $156.0M |
COO $118.5M |
WST $64.8M |
ICUI $60.1M |
TFX $56.5M |
RGEN $34.8M |
ANGO -$0 |
HAE -$33.1M |
| Trailing 4 Quarters Revenue | $19.8 Billion | 1/11 | BDX $19.8B |
RMD $4.5B |
HOLX $3.3B |
TFX $3.0B |
XRAY $2.9B |
WST $2.9B |
COO $2.9B |
ICUI $2.3B |
HAE $1.3B |
RGEN $602.4M |
ANGO $303.9M |
| Trailing 4 Quarters Earnings | $1.5 Billion | 1/11 | BDX $5.0B |
RMD $1.2B |
HOLX $1.0B |
COO $1.0B |
XRAY $984.0M |
TFX $749.7M |
WST $702.0M |
ICUI $595.8M |
HAE $336.2M |
RGEN $154.1M |
ANGO $71.0M |
| Quarterly Earnings Growth | 20% | 4/11 | HOLX 580% |
RMD 27% |
COO 23% |
BDX 20% |
HAE -7% |
TFX -28% |
WST -28% |
ANGO -42% |
RGEN -83% |
XRAY -105% |
ICUI -115% |
| Annual Earnings Growth | -18% | 6/11 | COO 76% |
HOLX 14% |
RMD 10% |
WST -9% |
HAE -11% |
BDX -18% |
TFX -23% |
ICUI -80% |
RGEN -102% |
ANGO -428% |
XRAY -1582% |
| Quarterly Revenue Growth | 2% | 6/11 | RMD 9% |
COO 8% |
HAE 8% |
ICUI 8% |
HOLX 3% |
BDX 2% |
TFX 1% |
RGEN -3% |
XRAY -4% |
WST -7% |
ANGO -12% |
| Annual Revenue Growth | 3% | 3/11 | HAE 9% |
TFX 5% |
BDX 3% |
RMD 2% |
ICUI 2% |
WST -1% |
ANGO -10% |
RGEN -15% |
COO -19% |
HOLX -20% |
XRAY -27% |
| Cash On Hand | $4.5 Billion | 1/11 | BDX $4.5B |
HOLX $2.4B |
RGEN $809.1M |
WST $446.2M |
HAE $344.4M |
ICUI $302.6M |
XRAY $279.0M |
TFX $238.6M |
RMD $238.4M |
COO $109.9M |
ANGO $76.1M |
| Short Term Debt | $1.2 Billion | 1/11 | BDX $1.2B |
XRAY $362.0M |
WST $154.1M |
TFX $93.8M |
RGEN $81.6M |
ICUI $69.9M |
COO $40.8M |
HOLX $40.7M |
RMD $35.2M |
HAE $5.1M |
ANGO -$0 |
| Long Term Debt | $18.1 Billion | 1/11 | BDX $18.1B |
COO $2.6B |
HOLX $2.5B |
XRAY $1.7B |
TFX $1.6B |
ICUI $1.6B |
HAE $1.2B |
RMD $838.8M |
RGEN $517.7M |
WST $72.9M |
ANGO $0 |
| PE | 47.50 | 2/11 | COO 59.75 |
BDX 47.50 |
TFX 43.61 |
WST 41.43 |
HAE 35.33 |
RMD 34.38 |
HOLX 26.41 |
XRAY -1.00 |
ANGO -1.00 |
ICUI -1.00 |
RGEN -1.00 |
| PS | 3.50 | 7/11 | RGEN 13.32 |
RMD 7.72 |
WST 7.56 |
COO 7.47 |
HOLX 5.70 |
TFX 3.82 |
BDX 3.50 |
HAE 3.04 |
ICUI 1.91 |
XRAY 1.75 |
ANGO 1.02 |
| PB | 2.68 | 7/11 | WST 8.44 |
RMD 7.22 |
HAE 4.48 |
RGEN 4.04 |
HOLX 3.74 |
COO 2.71 |
BDX 2.68 |
TFX 2.52 |
ICUI 2.16 |
XRAY 1.65 |
ANGO 1.51 |
| PC | 15.44 | 6/11 | COO 195.35 |
RMD 147.24 |
WST 48.74 |
TFX 48.18 |
XRAY 18.16 |
BDX 15.44 |
ICUI 14.56 |
HAE 11.78 |
RGEN 9.91 |
HOLX 7.60 |
ANGO 4.09 |
| Liabilities to Equity | 1.15 | 3/11 | HAE 1.81 |
XRAY 1.25 |
BDX 1.15 |
ICUI 1.10 |
HOLX 0.80 |
TFX 0.63 |
ANGO 0.55 |
COO 0.53 |
RGEN 0.44 |
RMD 0.41 |
WST 0.35 |
| ROA | 0.03 | 6/11 | RMD 15% | WST 15% | HOLX 8% | HAE 5% | TFX 4% | BDX 3% | COO 3% | RGEN 0% | ICUI -2% | XRAY -4% | ANGO -58% |
| ROE | 0.06 | 5/11 | RMD 21% |
WST 20% |
HOLX 14% |
HAE 13% |
BDX 6% |
TFX 6% |
COO 5% |
RGEN 0% |
ICUI -3% |
XRAY -8% |
ANGO -90% |
| Current Ratio | 1.87 | 9/11 | WST 3.82 |
RMD 3.42 |
RGEN 3.27 |
COO 2.89 |
ANGO 2.83 |
TFX 2.58 |
HOLX 2.26 |
ICUI 1.91 |
BDX 1.87 |
XRAY 1.80 |
HAE 1.55 |
| Quick Ratio | 0.18 | 6/11 | COO 59.75 |
BDX 47.50 |
TFX 43.61 |
WST 41.43 |
HAE 35.33 |
RMD 34.38 |
HOLX 26.41 |
XRAY -1.00 |
ANGO -1.00 |
ICUI -1.00 |
RGEN -1.00 |
| Long Term Debt to Equity | 0.70 | 3/11 | HAE} 1.35 |
ICUI} 0.76 |
BDX} 0.70 |
XRAY} 0.57 |
HOLX} 0.51 |
TFX} 0.36 |
COO} 0.33 |
RGEN} 0.26 |
RMD} 0.17 |
WST} 0.03 |
ANGO} 0.00 |
| Debt to Equity | 0.75 | 3/11 | HAE 1.35 |
ICUI 0.82 |
BDX 0.75 |
XRAY 0.72 |
HOLX 0.52 |
TFX 0.40 |
RGEN 0.37 |
COO 0.33 |
RMD 0.18 |
WST 0.12 |
ANGO 0.00 |
| Burn Rate | 8.37 | 5/11 | HAE 29.58 |
TFX 28.51 |
RGEN 21.41 |
COO 12.14 |
BDX 8.37 |
ANGO 5.66 |
ICUI 2.99 |
XRAY 1.70 |
RMD -0.95 |
WST -6.39 |
HOLX -29.00 |
| Cash to Cap | 0.06 | 6/11 | ANGO 0.24 |
HOLX 0.13 |
RGEN 0.10 |
HAE 0.08 |
ICUI 0.07 |
BDX 0.06 |
XRAY 0.06 |
TFX 0.02 |
WST 0.02 |
RMD 0.01 |
COO 0.01 |
| CCR | 2.23 | 2/11 | RGEN 10.48 |
BDX 2.23 |
HOLX 1.86 |
RMD 1.42 |
COO 1.13 |
TFX 0.71 |
WST 0.58 |
ANGO 0.00 |
HAE -0.86 |
ICUI -2.81 |
XRAY -39.00 |
| EV to EBITDA | 65.58 | 8/11 | RGEN} 393.53 |
WST} 127.38 |
RMD} 93.73 |
COO} 85.23 |
ICUI} 74.03 |
TFX} 67.31 |
HAE} 67.17 |
BDX} 65.58 |
HOLX} 55.47 |
XRAY} 44.03 |
ANGO} -72.67 |
| EV to Revenue | 4.24 | 7/11 | RGEN 13.21 |
COO 8.35 |
RMD 7.86 |
WST 7.51 |
HOLX 5.73 |
TFX 4.35 |
BDX 4.24 |
HAE 3.70 |
ICUI 2.51 |
XRAY 2.41 |
ANGO 0.77 |